Form 8-K - Current report:
SEC Accession No. 0000950170-23-018810
Filing Date
2023-05-08
Accepted
2023-05-08 16:11:11
Documents
14
Period of Report
2023-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K annx-20230508.htm   iXBRL 8-K 64654
2 EX-99.1 annx-ex99_1.htm EX-99 202426
3 GRAPHIC img193911374_0.jpg GRAPHIC 4354
  Complete submission text file 0000950170-23-018810.txt   407801

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT annx-20230508.xsd EX-101.SCH 2458
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT annx-20230508_pre.xml EX-101.PRE 11444
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT annx-20230508_lab.xml EX-101.LAB 14723
8 EXTRACTED XBRL INSTANCE DOCUMENT annx-20230508_htm.xml XML 4888
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 23897843
SIC: 2834 Pharmaceutical Preparations